ArticleFrontiers in oncology2026
Case Report: Definitive radiotherapy for intrathyroidal thymic carcinoma with neuroendocrine differentiation.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intrathyroidal thymic carcinoma (ITTC) with neuroendocrine differentiation is rare, and evidence for definitive radiotherapy in nonsurgical patients remains limited. A 70-year-old woman with a 1-year history of a neck mass and hoarseness was diagnosed with ITTC with neuroendocrine differentiation based on histopathological, immunohistochemical, and imaging findings. After declining surgery and systemic chemotherapy, she received definitive radiotherapy: 60 Gy in 30 fractions to the planning target volume, followed by a sequential boost of 6 Gy in 3 fractions to the gross primary tumor and involved lymph nodes, for a cumulative dose of 66 Gy in 33 fractions. No grade ≥3 acute treatment-related toxicities occurred. At approximately 2 months after radiotherapy, the sum of target-lesion diameters decreased from 54 mm to 42 mm, a 22.2% reduction. With no new lesions or unequivocal progression of non-target disease, the overall response was classified as stable disease according to RECIST 1.1. This case documents early radiographic tumor reduction following definitive radiotherapy for ITTC, although longer follow-up is required to assess the durability of disease control and late toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.